Chinese Journal of Tissue Engineering Research ›› 2017, Vol. 21 ›› Issue (21): 3438-3444.doi: 10.3969/j.issn.2095-4344.2017.21.026

Previous Articles    

Latest progress of chimeric antigen receptor modified T cells in the treatment of hematological malignancies

Hou Ping, Li Jian-ping   

  1. Liaoning Blood Center, Shenyang 110044, Liaoning Province, China
  • Revised:2017-02-17 Online:2017-07-28 Published:2017-08-02
  • Contact: Li Jian-ping, Chief physician, Liaoning Blood Center, Shenyang 110044, Liaoning Province, China
  • About author:Hou Ping, Master, Associate chief physician, Liaoning Blood Center, Shenyang 110044, Liaoning Province, China

Abstract:

BACKGROUND: In recent years, the use of chimeric antigen receptor modified T cells (CAR-T cells) has achieved good results in the treatment of hematological malignancies.
OBJECTIVE: To summarize the CAR-T technology, and its anti-tumor mechamism, progress in the treatment of hematological malignancies as well as its safety and coping strategies.
METHODS: A search of PubMed, CNKI, Wanfang by computer was performed for articles related to CAR-T published from January 2010 to January 2016, using the keywords of “CAR-T” in English and Chinese, respectively.
RESULTS AND CONCLUSION: The main principles that CAR-T cells fight against tumors are as follows: (1) resistance to immune escape through down-regulation of MHC; (2) production of interleukin-6, -10 indirectly influences the growth of tumor cells; and (3) tumor microenvironment changes inhibit tumor growth. The use of CAR-T in the treatment of hematological malignancies has been developed by leaps and bounds in recent years. Current studies concerning B cell lymphoma mainly focus on anti-CD19 CAR-T cells that have certain therapeutic effects on acute myeloid leukemia and acute lymphoblastic leukemia. However, its safety and effectiveness have yet to be studied.

 

 

Key words: Stem Cells, Neoplasms, Second Primary, Tissue Engineering

CLC Number: